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Background-—Vascular calciﬁcation resembles bone formation and involves vascular smooth muscle cell (SMC) transition to an
osteoblast-like phenotype to express Runx2, a master osteoblast transcription factor. One possible mechanism by which Runx2
protein expression is induced is downregulation of inhibitory microRNAs (miR).
Methods and Results-—Human coronary artery SMCs (CASMCs) treated with bone morphogenetic protein-2 (BMP-2; 100 ng/mL)
demonstrated a 1.7-fold (P<0.02) increase in Runx2 protein expression at 24 hours. A miR microarray and target prediction
database analysis independently identiﬁed miR-30b and miR-30c (miR-30b-c) as miRs that regulate Runx2 expression. Real-time–
polymerase chain reaction conﬁrmed that BMP-2 decreased miR-30b and miR-30c expression. A luciferase reporter assay veriﬁed
that both miR-30b and miR-30c bind to the 3′-untranslated region of Runx2 mRNA to regulate its expression. CASMCs transfected
with antagomirs to downregulate miR-30b-c demonstrated signiﬁcantly increased Runx2, intracellular calcium deposition, and
mineralization. Conversely, forced expression of miR-30b-c by transfection with pre–miR-30b-c prevented the increase in Runx2
expression and mineralization of SMCs. Calciﬁed human coronary arteries demonstrated higher levels of BMP-2 and lower levels of
miR-30b than did noncalciﬁed donor coronary arteries.
Conclusions-—BMP-2 downregulates miR-30b and miR-30c to increase Runx2 expression in CASMCs and promote mineralization.
Strategies that modulate expression of miR-30b and miR-30c may inﬂuence vascular calciﬁcation. (J Am Heart Assoc. 2012;1:
e003905 doi: 10.1161/JAHA.112.003905)
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V
ascular calciﬁcation is highly prevalent and is associated
with a 3- to 4-fold increased risk for cardiovascular
morbidity and mortality.
1 Although once viewed as a conse-
quence of calcium and phosphate imbalance resulting in
ectopicmineraldeposition,vascularcalciﬁcationisnowviewed
as a highly regulated process that recapitulates skeletal bone
formation.
2,3 The central role of vascular smooth muscle cell
(SMC) dedifferentiation to an osteoblast-like phenotype that
promotes vascular calciﬁcation has been demonstrated.
2–5
These osteoblast-like SMCs have decreased expression of smooth
muscle cell–speciﬁc markers, such as myocardin, smooth muscle
myosin heavy chain, and smooth muscle a-actin; and increased
expressionofbone-relatedproteins,includingalkalinephosphatase
and osteocalcin.
6
Runx2 is a master transcription factor of the calciﬁcation
program that induces differentiation of osteoblasts and chon-
drocytes.
7–9 In SMCs, Runx2 is not expressed under basal
conditionsbutisupregulatedinresponsetoprocalcifyingstimuli,
includinginﬂammation,oxidantstress,andbonemorphogenetic
protein-2(BMP-2).
10Runx2isexpressedinosteoblast-likeSMCs,
and upregulation of Runx2, rather than downregulation of
myocardin, drives SMC transition to osteoblast-like cells.
2–4,11
The mechanism by which Runx2 protein expression is regulated
in SMCs remains incompletely characterized.
MicroRNAs (miRs) are small noncoding sequences of 22
nucleotides that bind to the 3′-untranslated regions (UTRs) of
mRNAs to silence gene expression by inhibiting translation or
promoting degradation of target mRNAs.
12–15 miRs are comple-
mentarytothetargetmRNAsequenceandonlyrequirecomplete
complementarity of a 7-mer or 8-mer “seed sequence” for
binding to occur. There is evidence to support a role for miRs in
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ORIGINAL RESEARCHvascular calciﬁcation as miRs have been implicated in SMC
phenotype switching.
5,16,17 miRs have also been shown to
regulateRunx2expressionandosteoblastformationfrommurine
mesenchymal stem cells as well as to regulate osteoblast
differentiation.
18–21 To date, the relationship between miRs and
SMC Runx2 expression remains unknown. We, therefore,
hypothesizedthatBMP-2downregulatestheexpressionofselect
miRsthattargetthe3′-UTRofRunx2toinduceRunx2expression
and, thereby, SMC calciﬁcation.
Methods
Cell Culture
Human coronary artery smooth muscle cell (CASMCs; Lonza)
were maintained in smooth muscle basal medium (Lonza)
supplemented with 5% fetal bovine serum, 0.2% human basic
ﬁbroblastic growth factor, 0.1% insulin, and 0.1% human
epidermal growth factor without antibiotics at 37°Ci n5 %C O 2.
For von Kossa and intracellular calcium deposition studies,
mediumwassupplementedwith5 mmol/Lb-glycerophosphate.
Cellswerepassagedatconﬂuencewith0.5%trypsin/EDTAand
experiments were performed on cells from passages 3 to 7. In
select experiments, cells were stimulated with recombinant
human BMP-2 (R&D Systems; 0 to 200 ng/mL) or vehicle
control (4 mmol/L HCl, 0.1% BSA) for up to 14 days.
von Kossa Staining
Cells were ﬁxed with 10% formalin for 1 hour at 25°C. The
cells were then washed with distilled water, 3% silver nitrate
solution (Polysciences) was added to each well, and the cells
were exposed to UV light for 1 hour. The cells were next
washed with distilled water and sodium thiophosphate (5%)
was added for 5 minutes. Calcium-phosphate deposits were
detected as black-stained areas. Images were captured using
a VersaDoc (BioRad) scanning system, and densitometry was
performed using Adobe Photoshop CS2 software.
Intracellular Calcium Deposition
Cells were washed with PBS and decalciﬁed with 0.6 mmol/L
HCl at 4°C for 24 hours. Calcium released from the cell
cultures into the supernatant was determined colorimetrically
by the o-cresolphthalein method using the Calcium Colori-
metric Assay (BioVision). Calcium content was normalized to
total cell protein and expressed as lg/mg cell protein.
Transfection of miR Antagomirs and Precursors
To inhibit miR expression, cells were transfected with
antagomirs (100 pmol) of miR-30b (anti–miR-30b; Ambion),
miR-30c (anti–miR-30c; Ambion), or a combination of both
antagomirs (50 pmol), using the siPORT NeoFX transfection
reagent(Ambion) according to the manufacturer’s instructions.
Transfection using a random sequence anti-miR (Ambion) was
used as a negative control. Antagomirs were complexed with
the transfection reagent in Opti-MEM I Reduced Serum
Medium (Invitrogen) and added directly to CASMCs in fresh
full growth medium. Cells were then cultured for 48 hours
before treatment with BMP-2 (100 ng/mL) or vehicle control.
To force expression of the miRs, cells were transfected
with 100 pmol of mature miR-30b (pre–miR-30b; Ambion),
mature miR-30c (pre–miR-30c; Ambion), or a combination of
both pre-miRs (50 pmol), using the siPORT NeoFX transfec-
tion reagent (Ambion) according to the manufacturer’s
instructions. A random sequence pre-miR (Ambion) was used
as a negative control. Cells were treated as described for the
transfection of antagomirs.
Smad1 siRNA Transfection
To decrease Smad1 expression, CASMCs were transfected
with Smad1 Stealth Select RNAI siRNA (5′-GGAACUGCAA
CUACCAUCAUGGAUU-3′) or Stealth RNAI siRNA Negative
Control LO GC using Lipofectamine 2000 (Invitrogen) for
5 hours in OptiMEM I medium. After this time, cells were
placed in full growth medium and experiments were per-
formed after 48 hours.
mRNA and miR Isolation and Quantitative Real-
Time–Polymerase Chain Reaction
Total RNA containing miRs was prepared from cells using the
RNeasy RNA isolation kit (Qiagen) according to the manufac-
turer’s instructions. For the real-time–polymerase chain
reactions (RT-PCRs), 1 lg of RNA was used to generate
cDNA with oligo(dT) primers using the SuperScript III First-
Strand Synthesis System for RT-PCR (Invitrogen). Quantitative
RT-PCR was performed using 1 ng of ﬁrst-strand cDNA,
TaqMan Universal Master Mix, and 20X TaqMan Runx2 or
GAPDH Gene Expression Assays (Applied Biosystems).
Samples were run on an Applied Biosystems 7900 HT Fast
RT-PCR system. Quantitation of data was performed using the
comparative CT (ΔΔCT) method using GAPDH gene expression
as an endogenous reference.
Mature miRNA expression levels were also analyzed by
quantitative RT-PCR using TaqMan miR assays (Applied
Biosystems) for human miR-30a, miR-30b, miR-30c, miR-30d,
or miR-30e (Applied Biosystems) using the TaqMan miR
reverse transcription kit (Applied Biosystems) according to
the manufacturer’s instructions. Real-time PCR was performed
on the resulting complementary DNA using miR-30a, miR-30b,
miR-30c, miR-30d, miR-30e, or RNU48 TaqMan miRNA Gene
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Samples were run on in a 7900 HT Fast Real-Time PCR system
(Applied Biosystems) in 9600 Emulation mode. Quantitation of
data was performed using the comparative CT (ΔΔCT) method
using RNU48 expression as the endogenous reference.
miR Microarray
miR microarray was performed using the Human MiRNA
Genome V2.0 Complete RT
2 PCR Array, which includes 752
expressed human miRs, according to the manufacturer’s
instructions (SABiosciences). Data were analyzed using soft-
ware provided by the manufacturer and ﬁndings were
conﬁrmed in a duplicate experiment.
Luciferase Reporter Assay
COS7 cells (ATCC) were grown to 50% conﬂuence in 6-well
plates in high-glucose Dulbecco’s Modiﬁed Eagle’s Medium
(Invitrogen) supplemented with 10% fetal bovine serum. Cells
were transfected with 1000 ng of a reporter plasmid
containing the 3′-UTR sequence of Runx2 (NM_001015051)
that was cloned downstream of the ﬁreﬂy luciferase gene
using Lipofectamine 2000. Cells were cotransfected with
10 nmol/L pre–miR-30b, pre–miR-30c, both pre-miRs
(5 nmol/L each), or a negative control (Ambion). After
48 hours, ﬁreﬂy luciferase was measured in cell lysates using
the britelite plus Reporter Gene Assay System (PerkinElmer)
and a 20/20
n Turner BioSystems Luminometer.
Western Immunoblotting and Densitometry
Cells were harvested and centrifuged at 1000g at 4°C for
5 minutes, after which the supernatant was discarded and
the samples were frozen at 80°C overnight. The pellet was
homogenized and 20 to 50 lg cell protein was added per
lane. Proteins were size-fractionated electrophoretically using
SDS-PAGE and transferred to polyvinylidene ﬂuoride
membranes. After blocking with 5% skim milk, the polyviny-
lidene ﬂuoride membranes were incubated with antibodies to
smooth muscle myosin heavy chain, smooth muscle a-actin,
desmin, tubulin, Runx2, actin, osteopontin, or osteocalcin
(Abcam), and visualized using the enhanced chemilu-
minescent system (Amersham Biosciences). Densitometry
was performed on a minimum of 3 immunoblots using
a VersaDoc (BioRad) scanning system to quantify band
density.
Alkaline Phosphatase Activity
Alkaline phosphatase activity was assayed using 5-bromo-
4-chloro-3′-indolyphosphate (BCIP) and nitro-blue tetrazolium
(NBT), which in combination yield an intense black-purple
color when reacted with alkaline phosphatase. Brieﬂy, cells
were washed twice with phosphate buffered saline, ﬁxed with
10% formalin for 1 hour at 25°C, and washed in water.
Samples were then incubated with BCIP/NBT (Promega) for
30 minutes and processed according to the manufacturer’s
instructions. Images of 3 random 910 ﬁelds were captured
using a Nikon TMS microscope equipped with a Nikon Coolpix
4300 camera. Colorimetric detection of alkaline phospha-
tase activity was quantiﬁed using Adobe Photoshop CS2
software.
Human Coronary Artery Specimens
Human coronary artery sections were isolated at the time of
explant, immediately snap frozen in liquid nitrogen, and
maintained in a tissue bank with institutional review board
approval from Partners Human Research Committee and
Mount Sinai School of Medicine. Calciﬁcation was detected
by incubation with Alizarin Red (American Mastertech
Scientiﬁc) for 5 minutes according to manufacturer’s instruc-
tions. For immunohistochemistry, 2-mm sections were ﬁxed
in formalin for 24 hours and embedded in parafﬁn, and 5-lm
sections were immunostained for detection of BMP-2
(Abcam). In situ hybridization for detection of miR-30b was
performed by treating deparafﬁnized and rehydrated sections
with proteinase K (10 lg/mL) for 15 minutes at 25°C.
Samples were incubated with hybridization buffer (Sigma) for
1 hour followed by overnight incubation with 10 nmol/L
miR-30b or scramble miRCURY LNA Detection probes, FAM-
labeled (EXIQON) at 55°C. Immunodetection was performed
using an anti-FITC horseradish peroxidase–conjugated anti-
body (1:100; DAKO) followed by tyramide (PerkinElmer)
ampliﬁcation. Sections were then incubated with NeutrAvidin-
conjugated alkaline phosphatase (1:200; Thermo Scientiﬁc)
in maleate buffer and NBT/BCIP (Roche) to visualize
miR-30b. Slides were left at room temperature for 24 hours,
and dark purple areas were considered to be positive
staining. Images were captured at 9100 using an Olympus
BX51 microscope equipped with PictureTaker software.
Statistical Analysis
All experiments were performed a minimum of 3 times in
duplicate. The Shapiro–Wilk test was used to test normality.
Data are presented as the meanSEM, and ≥2 independent
groups were compared using an unpaired Student t test or
1-way ANOVA, respectively, followed by a post hoc Tukey
test. A repeated- measures ANOVA was used for comparisons
over time. All analyses were performed using Origin 8.5
software (OriginLab). A P value of <0.05 was considered
signiﬁcant.
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BMP-2 Promotes Calciﬁcation of CASMCs by
Increasing Runx2 Expression
To establish the dose–response and time course of BMP-2–
mediated calciﬁcation of CASMCs, we treated cells with
increasing concentrations of BMP-2 and examined calciﬁca-
tion by von Kossa staining after 14 days. In CASMCs treated
with BMP-2 (0, 50, 100, or 200 ng/mL), there was a dose-
dependent increase in calciﬁcation with a maximal effect
observed in cells treated with BMP-2 (100 ng/mL; Fig-
ure 1A). We therefore elected to perform further studies in
cells treated with this dose. Mineralization was associated
with an increase in intracellular Ca
2+ deposition in BMP-2–
treated CASMCs after 7 days (5.21.2 lg/mg vs
62.44.9 lg/mg protein, P<0.01) that was elevated further
after 14 days (144.721.3 lg/mg protein, P<0.01;
Figure 1B). Consistent with CASMC transition to an osteo-
blast-like phenotype, there was a decrease in the expression
of the smooth muscle–speciﬁc markers, smooth muscle
myosin heavy chain, smooth muscle a-actin, and desmin
that was apparent after 14 days (Figure 1C). Thus, under
these experimental conditions, BMP-2 increased CASMC
calciﬁcation in vitro.
BMP-2 Increases Runx2 Expression by
Downregulating miR-30b-c
As Runx2 expression is necessary for vascular SMC transition
to a calcifying phenotype,
4,11 we examined Runx2 mRNA and
protein expression in BMP-2–stimulated cells. BMP-2
increased Runx2 mRNA levels by 5.5-fold at 4 hours and a
13.1-fold by 24 hours compared with vehicle-treated cells
(P<0.01; Figure 1D). While Runx2 protein was not expressed
in vehicle-treated cells, in BMP-2–treated cells Runx2 protein
expression was evident at 24 hours (1.70.4-fold, P<0.02;
Figure 1E).
Next, to determine if BMP-2 increased Runx2 expression
by downregulating the expression of inhibitory miRs, we
treated CASMCs with BMP-2 for 4 hours and performed an
miR microarray to identify candidates that were downregu-
lated by BMP-2. Of 11 miRs predicted to target the 3′-UTR of
human Runx2 (miRbase, TargetScan),
22–25 the microarray
revealed that 7 miRs were poorly expressed in CASMCs
(miR-133, miR-205, miR-338, miR-135, miR-203, miR-202,
and miR-207) and that BMP-2 did not signiﬁcantly change the
expression of 3 miRs (miR-23, miR-218, and miR-34);
however, BMP-2 decreased the expression of miR-30b by
6.2-fold (P<0.01) and miR-30c by 5.5-fold (P<0.01) compared
with untreated CASMCs. Given that members of the miR-30
family (miR-30a-e) share a similar seed sequence, we
conﬁrmed the microarray results using qRT-PCR to assess
changes in miR-30a-e expression. In CASMCs treated with
BMP-2 for up to 4 hours, there was a signiﬁcant decrease in
miR-30b (43%, P<0.01) and miR-30c (34%, P<0.01) expres-
sion; however, there was no decrease in miR30a, miR30d, or
miR30e expression levels (Figure 2A). Expression of miR30b
(Figure 2B) and miR30c (Figure 2C) was dowregulated signif-
icantly by BMP-2 after 2 hours, before the observed upreg-
ulation of Runx2 mRNA, indicating that these miRs are
plausible candidates to regulate Runx2 expression.
BMP-2 is also known to activate Smad signaling, and
Smads have been implicated in the regulation of miR
expression, albeit by increasing miR maturation.
26 Therefore,
we next examined Smad 1/5/8 activation in BMP-2–stimulated
CASMCs (Figure 3). Here, we found that BMP-2 increased
phosphorylation of Smad 1/5/8 with no change in Smad 4
expression. To conﬁrm that downregulation of miR-30b and
miR-30c occurred through an Smad-independent pathway, we
transfected CASMCs with an siRNA to decrease Smad1 mRNA
levels by 87% and protein expression by 68%, or a control
siRNA (Figure 4), and incubated cells with BMP-2 for 4 hours.
In control-transfected cells, BMP-2 decreased miR-30b
expression by 58.53.4% (P<0.01), and downregulation of
Smad1 had no further effect (64.63.9%, P=0.2). Similarly,
BMP-2 downregulated expression of miR-30c by 63.42.9%
(P<0.01) in control-transfected cells, with no further decrease
observed in Smad1 siRNA-transfected cells (66.52.0%,
P=0.2).
miR-30b-c Modulates Runx2 Protein Expression
To demonstrate that miR-30b and miR-30c play a role in
modulating Runx2 expression, we ﬁrst transfected CASMCs
with antagomirs to miR-30b, miR-30c, or both, to inhibit their
expression by 98%, 95%, or 98%, respectively, compared with
cells transfected with a scrambled sequence control miRNA.
Compared with control-transfected cells, downregulation of
miR-30b or miR-30c, either alone or in combination, resulted
in an increase in Runx2 protein expression in the absence of
BMP-2-stimulation (Figure 5A). In cells that were treated with
BMP-2 for 24 hours, inhibition of miR-30b or miR-30c, alone
or in combination, resulted in an increase in Runx2 expression
that was greater than that observed with BMP-2 stimulation
alone (Figure 5B).
To conﬁrm these ﬁndings, we next transfected cells with
mature miR-30b, mature miR-30c, or both, to force expression
of these miRs to levels 4.8-fold, 4.5-fold, and 4.6-fold,
respectively, compared with CASMCs transfected with a
scrambled control mature miR. In CASMCs, forced expression
of miR-30b or miR-30c, alone or in combination, decreased or
prevented the induction of Runx2 (Figure 6A). When CASMCs
were stimulated with BMP-2 for 24 hours, forced expression
of miR-30b or miR-30c limited Runx2 protein expression
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miR-30b and miR-30c are endogenous regulators of Runx2
protein expression.
miR-30b-c Target Runx2 Through a Site in the
3′-UTR
Review of the human Runx2 3′-UTR revealed that there were
conserved binding sites for miR-30b-c. To demonstrate that
miR-30b and miR-30c bind to the Runx2 3′-UTR directly as a
mechanism by which to modulate Runx2 expression, we
cotransfected COS7 cells with a luciferase reporter plasmid
containing the Runx2 3′-UTR with mature miR-30b, miR-30c,
both, or a scrambled sequence negative control miR. In this
assay, binding of miR-30b or miR-30c to the 3′-UTR inhibits
luciferase expression and luminosity is diminished. Compared
with scrambled control-transfected cells, we found that forced
expression of miR-30b, miR-30c or both decreased luminosity
signiﬁcantly (100.01.0% vs 64.16.2% vs 61.25.2% vs
58.16.7%, P<0.04), indicating that miR-30b-c bind to the
3′-UTR of Runx2 to inhibit translation (Figure 7).
miR-30b-c Knockdown Increases Expression of
Runx2 Target Genes and CASMC Calciﬁcation
To evaluate the functional consequences of modulating
miR-30b and miR-30c expression, and thereby Runx2, we
ﬁrst transfected CASMCs with antagomirs to miR-30b or miR-30c
for 14 days and examined the expression of the Runx2 target
genes osteopontin and osteocalcin. In the absence of
exogenous BMP-2, there was an increase in the expression
of both osteopontin and osteocalcin (Figure 8A). We next
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Figure 1. BMP-2 increases Runx2 expression and calciﬁcation of human coronary artery smooth muscle cells (CASMCs). A, Human CASMCs
were treated with BMP-2 (0, 50, 100 or 200 ng/mL) for 14 days and calciﬁcation was assessed by von Kossa staining. Representative images are
shown (n=4). B, Cellular calcium levels were assessed in CASMCs treated with BMP-2 (100 ng/mL) for up to 14 days. *P<0.01 vs day 0 (n=4). C,
CASMC transition to a calcifying phenotype was conﬁrmed by examining expression of smooth muscle myosin heavy chain (SM-MHC), smooth
muscle a-actin (SM a-actin), and desmin. Tubulin expression levels were examined as loading controls and representative blots are shown (n=3).
D, Runx2 mRNA expression was measured by quantitative real-time–polymerase chain reaction in CASMCs treated with BMP-2 (100 ng/mL) for
up to 24 hours (n=6) and E, corresponding protein levels were evaluated at 24 hours. Representative blots are shown (n=4). *P<0.01 vs 0 hour.
BMP-2 indicates bone morphogenetic protein-2.
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2+ deposition in CASMCs transfected
with antagomirs to miR-30b and miR-30c. Compared with
scrambled control-transfected cells, even in the absence of
BMP-2 stimulation, downregulation of miR-30b, miR-30c, or
both increased Ca
2+ deposition (Figure 8B). We also exam-
ined calciﬁcation by von Kossa staining after 14 days. Here,
we found that downregulation of the expression of miR-30b,
miR-30c, or both resulted in an increase in calciﬁcation
compared with scrambled control transfected cells (1.00.1
vs 3.20.2 vs 2.80.2 vs 2.50.5-fold, P<0.01; Figure 8C);
however, this increase was abrogated compared with what
was observed in BMP-2–simulated scrambled control-trans-
fected CASMCs (Figure 8C).
To explain the observed difference in the degree of
calciﬁcation by von Kossa staining between CASMCs with
decreased expression of miR-30b or miR-30c and BMP-2–
stimulated CASMCs, we examined the expression and activity
of alkaline phosphatase, a Runx2-independent calciﬁcation
protein that is necessary for mineralization. Compared with
scrambled control transfected CASMCs, in cells transfected
with antagomirs to miR-30b, miR-30c, or both, there was
no observed increase in alkaline phosphatase expression
(Figure 9A) or activity (1.00.0 vs 1.20.2 vs 1.10.1 vs
1.00.0-fold, P=0.93). In contrast, in BMP-2–stimulated
CASMCs, there was an increase in alkaline phosphatase
expression (Figure 9B) and activity (2.60.2-fold, P<0.01)
that was not augmented further by downregulation of miR-30b
(2.10.1-fold), miR-30c (1.90.2-fold), or both (1.90.2-fold;
Figure 8D). Similarly, compared with scrambled control-
transfected CASMCs, forced expression of miR-30b, miR-
30c, or both had no effect on alkaline phosphatase activity at
baseline (1.00.0 vs 1.10.1 vs 0.90.1 vs 1.00.1-fold,
P=0.96) or following treatment with BMP-2 (2.20.1 vs
2.00.1 vs 2.40.2-fold, P<0.01 vs BMP-2).
miR-30b Is Downregulated in Human Coronary
Artery Atherosclerosis
To demonstrate the in vivo relevance of our ﬁndings in
CASMCs, we next examined human coronary arteries
obtained at the time of explant for evidence of calciﬁcation.
Compared with nonatherosclerotic donor human coronary
arteries (n=3), atherosclerotic arteries from patients with
cardiomyopathy (n=3) had evidence of vascular calciﬁcation
by Alizarin Red staining (Figure 10). In calciﬁed atheroscle-
rotic vessels, there was an associated increase in BMP-2
expression and a concomitant decrease in miR-30b expres-
sion as detected by in situ hybridization compared with the
donor vessels (Figure 10).
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Figure 2. BMP-2 decreases miR-30b and miR-30c expression.
Human CASMCs were treated with BMP-2 (100 ng/mL) for 4 hours
and (A) expression of miR30 family members (miR-30a, miR-30b,
miR-30c, miR-30d, and miR-30e) was evaluated by quantitative real-
time–polymerase chain reaction ( PCR). *P<0.01 vs untreated, (n=4).
(B, C) To determine the temporal relationship between changes in
Runx2 and miR-30b and miR-30c expression, CASMCs were treated
with BMP-2 (100 ng/mL) for up to 4 hours and miR-30b and
miR-30c expression was measured by quantitative real-time PCR.
*P<0.01 vs 0 hour (n=4). BMP-2 indicates bone morphogenetic
protein-2; CASMC, coronary artery smooth muscle cell; miR,
microRNA.
Figure 3. BMP-2 increases Smad 1/5/8 activation. Human coro-
nary artery smooth muscle cells were treated with BMP-2 and
phosphorylation of Smad 1/5/8 (p-Smad 1/5/8) was examined up
to 30 minutes. Total levels of Smad 1/5/8 and of the regulatory
Smad, Smad 4, were also examined. Representative blots are shown
(n=3). BMP-2 indicates bone morphogenetic protein-2.
Smad 1
Actin
CTL          Smad 1
siRNA         siRNA
Figure 4. Smad1 siRNA transfection. Human coronary artery
smooth muscle cells were transfected with Smad1 siRNA or a
scrambled control siRNA (CTL siRNA) and Smad1 expression was
examined after 24 hours. A representative blot is shown (n=3).
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In our study, we found that BMP-2 downregulates miR-30b
and miR-30c to increase Runx2 protein expression and
promote CASMC calciﬁcation. BMP-2 downregulates miR-30b
and miR-30c after 2 hours, a time point before the observed
increase in Runx2 expression. Using a luciferase reporter
assay, we also demonstrated that miR-30b and miR-30c bind
to the Runx2 3′-UTR to repress Runx2 mRNA translation. By
transfecting CASMCs with antagomirs to miR-30b and
miR-30c, in the absence of BMP-2 stimulation, we demon-
strated that downregulation of these miRs is sufﬁcient to
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Figure 5. miR-30b or miR-30c knockdown increases Runx2 protein
expression. Human CASMCs were transfected with an antagomir to
miR-30b (anti–miR-30b), to miR-30c (anti–miR-30c), or to both, or
with a scrambled miR sequence (SS) as a control. Runx2 protein
levels were determined (A) under basal conditions after 24 hours or
(B) following stimulation with BMP-2 (100 ng/mL) for 24 hours.
Densitometry was performed on a minimum of 3 independent blots.
Representative blots are shown. *P<0.01 vs SS. BMP-2 indicates
bone morphogenetic protein-2; CASMC, coronary artery smooth
muscle cell; miR, microRNA.
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Figure 6. miR-30b-c forced expression decreases Runx2 protein
expression. Human CASMCs were transfected with pre–miR-30b,
pre–miR-30c, or both, or with a scrambled miR sequence (SS) as a
control. Runx2 protein levels were evaluated (A) under basal
conditions after 24 hours or (B) following stimulation with BMP-2
(100 ng/mL) for 24 hours. Densitometry was performed on a
minimum of 3 independent blots. Representative blots are shown.
*P<0.01 vs SS. BMP-2 indicates bone morphogenetic protein-2;
CASMC, coronary artery smooth muscle cell; miR, microRNA.
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Hincrease Runx2 expression. This, in turn, resulted in increased
expression of the Runx2-dependent genes osteopontin and
osteocalcin, increased intracellular Ca
2+ deposition, and
CASMC calciﬁcation. Interestingly, CASMC calciﬁcation
following downregulation of miR-30b or miR30c alone was
less than that observed in BMP-2–stimulated cells, likely
owing to the observation that downregulation of miR-30b or
miR-30c alone did not increase alkaline phosphatase activity,
a ﬁnding that has been reported by other investigators.
20
Nonetheless, basal levels of alkaline phosphatase activity
were adequate to promote intracellular Ca
2+ deposition
consistent with CASMC calciﬁcation. Moreover, we demon-
strated that these ﬁndings have relevance for atherosclerotic
coronary artery disease by conﬁrming a decrease in miR-30b
expression in human coronary arteries that was associated
with increased BMP-2 expression and vascular calciﬁcation.
That BMP-2 downregulates miRs, in particular miR-30b and
miR-30c, to increase Runx2 expression in CASMCs is
consistent with work in other cell types directly related to
bone formation. For example, BMP-2, a member of the
transforming growth factor-b superfamily, stimulates osteo-
blastic differentiation in vitro and increases the expression of
genes encoding osteoblast phenotype-related proteins.
21,27
Findings from several studies provide evidence to demon-
strate that BMP-2 modulates miR expression to increase the
expression of osteoblast phenotype-related proteins and
initiate osteogenesis.
19 In C2C12 cells, BMP-2 promotes
osteogenic differentiation by decreasing miR-133 expression
to increase Runx2 as well as downregulating miR-206
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Figure 7. miR-30b-c targets Runx2 through a site at the 3′ -UTR. A
reporter plasmid construct containing the Runx2 3′ -UTR and pre–
miR-30b, pre–miR-30c, or both, were co-transfected into COS7 cells.
A scrambled miRNA sequence (SS) served as the negative control. In
this assay, decreased luminosity indicates miRNA binding to the 3′ -
UTR. Relative ﬂuorescence units (RFUs) were compared against SS.
*P<0.04 vs SS. miR indicates microRNA.
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Figure 8. miR-30b-c knockdown increases expression of Runx2 target proteins and calciﬁcation of human coronary artery smooth muscle cells.
Human CASMC were transfected with an antagomir to miR-30b (anti-miR-30b), to miR-30c (anti-miR-30c), to both, or with a scrambled miRNA
sequence (SS). After 14 days (A) expression of the Runx2 target proteins osteopontin and osteocalcin was examined. Actin expression levels were
examined as a loading control and representative blots are shown (n=3). B, Calcium levels were determined (*P<0.01 vs SS, n=4); and, in the
presence or absence of BMP-2 (100 ng/mL) for the 14-day treatment period, (C) calciﬁcation was evaluated by von Kossa staining (n=3) and (D)
activity of the Runx2-independent protein alkaline phosphatase was assessed using BCIP/NCP staining at 109 magniﬁcation (n=4). *P<0.01 vs
SS. BMP-2 indicates bone morphogenetic protein-2; CASMC, coronary artery smooth muscle cell; BCIP, 5-bromo-4-chloro-3′-indolyphosphate;
miR, microRNA; NBT, nitro-blue tetrazolium.
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marker proteins.
19,28–30 In preosteoblast MC3T3-E1 cells,
BMP-2 decreased miR-208 to regulate Ets-1 and osteogenic
differentiation.
31 In contrast, BMP-2 was also shown to
regulate Runx2 expression by upregulating miR-3960 expres-
sion. This, in turn, resulted in decreased expression of
homeobox A2, a repressor of Runx2 expression.
32 In our
study, we did not examine the role of the aforementioned
miRs in modulating Runx2 expression, as they were not
identiﬁed by the miR microarray as likely candidates in SMCs;
however, this does not exclude the possibility that they may
be important for SMC calciﬁcation. Moreover, results from
these studies may not be broadly applicable to vascular
calciﬁcation as they were conducted using different primary
cells, or cell lines, and culture conditions, and different
durations of BMP-2 exposure, and each focused on a different
candidate miR. It remains more likely that in SMCs, BMP-2
downregulates the expression of a panel of miRs that affect
several targets to promote osteogenic differentiation and
calciﬁcation.
Microarray and bioinformatic analyses identiﬁed miR-30b
and miR-30c as key regulators of Runx2 expression in BMP-2–
stimulated CASMCs. Importantly, while the Runx2 3′-UTR
contains >1 site that is complementary to the seed sequence
shared by the miR-30 family, we found no difference in Runx2
expression when we combined miR-30b and miR-30c antag-
omirs or pre-miRs. This result suggests that there is no
additivity or cooperativity between miR-30b and miR-30c to
downregulate Runx2 and is consistent with the shared seed
sequence within the miR-30 family. Our ﬁndings are also in
line with prior studies that identiﬁed members of the miR-30
family (miR-30a, miR-30d, miR-30e) that were downregulated
by BMP-2 or involved in osteogenic differentiation. For
example, BMP-2–downregulated miR-30a and miR-30d in
murine C2C12 cells and, more recently, miR-30c was
identiﬁed as part of a program of miRs that target Runx2 to
control osteoblast maturation and are inversely expressed in
relation to Runx2 expression.
18–20 Here, miR-30c expression
in murine MC3T3-1 premature osteoblasts, ATDC5 chondro-
cytes, or NIH3T3 ﬁbroblasts was shown to downregulate
Runx2 expression to a different degree in each cell type. This
ﬁnding suggests that the effect of miR-30c on Runx2
expression may have cell or tissue speciﬁcity.
20 In addition,
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Figure 9. Alkaline phosphatase expression. Human coronary artery
smooth muscle cells were transfected with a scrambled control
antagomir (SS), antagomirs to miR-30b, miR-30c, or both and alkaline
phosphatase expression was examined after 14 days in (A) the
absence of BMP-2 or (B) in cells treated with BMP-2. Representative
blots areshown(n=3). BMP-2 indicatesbonemorphogenetic protein-2.
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Figure 10. miR-30b is downregulated in human coronary artery atherosclerosis. Human coronary arteries were isolated at the time of explant
from donors without atherosclerotic coronary artery disease (n=3) and individuals with atherosclerotic coronary disease and cardiomyopathy
(n=3). Calciﬁcation was assessed using Alizarin Red. BMP-2 expression was determined by immunohistochemistry and miR-30b expression was
examined by in situ hybridization. Representative images are shown. BPM-2 indicates bone morphogenetic protein-2; CM, cardiomyopathy; miR,
microRNA.
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30c, it is also possible that other targets of miR-30b or miR-
30c not examined in our study mediate CASMC calciﬁcation.
The mechanism(s) by which miR-30b and miR-30c expres-
sion is downregulated by BMP-2 remains unclear. We
investigated Smad signaling as one possible mechanism as
Smad1/5 signaling has been shown to be involved in miR
processing, albeit to increase miR maturation by Drosha.
26,33,34
Our results do not support a role for Smad1 in the BMP-
2–mediated downregulation of miR-30b and miR-30c as
transfection of cells with an siRNA to Smad1 had no effect
on miR-30b or miR-30c expression in CASMCs. The difference
between our ﬁndings and prior studies may be explained, in
part, by the observation that miR-30b and miR-30c were not
identiﬁed as miRs that contain a conserved or variant
regulatory Smad binding element that was present in the
miRs regulated by Smad signaling.
26 It is also possible that
miR-30b and miR-30c expression is modulated by transcrip-
tional regulation. In a screening study of 175 human miRs,
one-third of intronic miRs were found to have transcription
initiation regions independent from their host promoters. In
this study, human miR-30c1 and miR-30e were identiﬁed as
miRs that have conserved intronic miRNA clusters using
independent intronic promoters.
35 miR-30b is an intergenic
miR located in 8q24.22 (135 812 850: 135 812 763)
between the protein coding regions for ZFAT and ribosomal
protein L23 pseudogene 56 (RPL23AP56). Mature miR-30c
may be produced by 2 transcripts: miR-30c1 (Gene ID:
407031) in 1p34.2 (41 222 956; 41 223 044), which is
intronic and overlaps with nuclear transcription factor Y,
c subunit, and miR-30c2 (Gene ID: 407032), which is intronic
and is located in 6q13 (72 084 663:72 088 734) between
the genes for opioid growth factor receptor-like 1 and
RP1-288M22.2, a processed transcript for which there is no
protein product. This suggests that elements that regulate
transcription of both the primary transcripts as well as
neighboring genes may also regulate miR-30b or miR-30c
transcription.
In summary, we ﬁnd that BMP-2 downregulates miR-30b
and miR-30c to increase Runx2 expression and promote
CASMC calciﬁcation. The ﬁnding that these miRs regulate
acquisition of an osteoblast-like phenotype in SMCs and other
cell types, including preosteoblast cells and chondrocytes,
conﬁrms the tenet that vascular calciﬁcation recapitulates
bone formation. These studies also identify miR-30b and
miR-30c as potential candidates to modulate ectopic vascular
calciﬁcation that may be associated with comorbid diseases,
such as diabetes mellitus and end-stage renal disease. Finally,
owing to the similarities between osteoblast and SMC miR-
30b-c and Runx2 expression, additional study is warranted to
determine if there are tissue-speciﬁc features or regulators of
these miRs to allow for targeted miR-speciﬁc interventions to
modulate vascular calciﬁcation without inﬂuencing endochon-
dral bone formation.
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